Novel Relapsed/Refractory CLL Therapies Have Similar Safety Profiles
A new comparison of the safety profiles of novel targeted therapies for relapsed or refractory chronic lymphocytic leukemia (R/R CLL) suggests they all have similar—and favorable—safety profiles. The report, which was published in Therapeutic Advances …